A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2018
At a glance
- Drugs Binimetinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 26 Sep 2018 Results (n=11) of 3+3 dose-escalation design presented at the 19th World Conference on Lung Cancer.
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2018 Status changed from not yet recruiting to recruiting.